Slide 1: CSL Limited 2018 Full Year Results
For personal use only CSL Limited 2018 Full Year Results 15 August 2018 CEO – Paul Perreault CFO – David Lamont
Slide 2: Legal Notice
Legal Notice For personal use only Forward looking statements The materials in this presentation speak only as of the date of these materials, and include forward looking statements about CSL Limited and its related bodies corporate (CSL) financial results and estimates, business prospects and produ
Slide 3: Delivering on Strategy
Delivering on Strategy For personal use only Growth Innovation People & Culture • Ig sales +11%1 • PRIVIGEN® approved for • Forbes Magazine Top 50 • IDELVION® exceeded forecast CIDP in US employer in the world • Specialty Products +24%1 • HIZENTRA® approved for • Workforce +15% - KCENTRA® & HAEGARDA
Slide 4: Growth: CSL Behring Sales FY18
Growth CSL Behring Sales FY18 For personal use only Therapeutic Group Region Sales % 18% Therapy $m Change1 EM 9% Immunoglobulins 3,145 11% Haemophilia 1,113 5% North 12% America 12% Asia Pac 46% Albumin 921 7% 17% US$6.7b Specialty 1,490 24% Other 9 Total 6,678 11% EU 28% 8% 1. Growth percentages s
Slide 5: Immunoglobulin Growth
Immunoglobulin Growth Sales up 11%1 For personal use only Ig volume by indication • 13% growth1 • 12% growth1 Other CIDP • Launched CIDP US • Most used SCIG • Increased diagnosis & awareness - ~60% new starts SID PID - Primary Immune Deficiency • First & only SCIG in CIDP - Secondary Immune Deficien
Slide 6: Haemophilia Growth
Haemophilia Growth Sales up 5%1 For personal use only • Fast becoming standard of care • Launched in 14 countries • Market leader in a number of • Accelerating adoption countries • Competitive market • Over 1,100 patients on product • Transition from • Market share ~40% average HELIXATE® to AFSTYLA®
Slide 7: Albumin Growth
Albumin Growth Sales up 7%1 For personal use only China CHINA • Sales up 11%1 • ~26,000 Hospitals: - ~6,500 regularly • Continued expansion into Tier 2 & 3 cities purchasing CSL albumin • ~450,000 pharmacies: Europe - ~2,500 regular CSL • Use of starches restricted albumin sellers - Intensive Care U
Slide 8: Specialty Products Growth
Specialty Products Growth Sales up 24%1 For personal use only Treated ~4,700 • Launched in 11 EU • Most successful chronic drug launch • US sales +22%1 countries in the US in past 5 years. ~50% US • Rapid adoption in Japan • Global sales +9%1 prophylactic market share - ~650 hospitals • Self adminis
Slide 9: Efficiency
Efficiency Efficiency For personal use only CSL PLASMA MANUFACTURING • Total CSL collection centres 206 • Group wide capital projects on track - 27 centres opened during FY18 - Unmatched in the industry - 35% of total US centre openings in FY18 • New Donor Management System delivering faster donatio
Slide 10: Innovation: Transplant
Innovation Innovation For personal use only TRANSPLANT No. of US Patients Undergoing Transplant Annually Compared With No. of Patients on the Waiting List • Emerging franchise 140,000 • High unmet need 120,000 100,000 • Leverages existing products 80,000 100,000 • Vitaeris collaboration 60,000 50,00
Slide 11: Innovation: CSL112, CSL730, Gene Therapy
Innovation Innovation For personal use only CSL112 CSL730 GENE THERAPY • Phase 3 study • Fc Multimer: • Calimmune acquisition commenced: - Provides improved • Proprietary stem cell - ~17,400 patients target binding gene therapy platform - 40 countries • Phase 1 trial • Differentiating • First patien
Slide 12: Seqirus Revenue FY18
Seqirus Seqirus Revenue FY18 For personal use only $m Category Region 1,200 20% 1,000 +30%1 EM 6% 3PL Other 800 Fluad 600 North 78% TIV 11% Asia Pac US$1.1b America (ADJ 3PL) 22% 61% 400 QIV 200 Pandemic EU 11% 0 FY17 FY17a FY18 Switch to QIV & Fluad Pandemic earnings growth 6% 1. Growth shown at co
Slide 13: Seqirus – Operational Highlights
Seqirus – Operational Highlights Seqirus For personal use only FLUCELVAX® • Innovative use of cell-derived starting viruses • Production up four fold, with plans to further boost antigen capacity • Real world data showing potential for better effectiveness than traditional options • EU launch prepar
Slide 14: Financials
For personal use only Financials David Lamont - CFO 14 | Driven by Our Promise™
Slide 15: Financial Highlights – NPAT
Financial Highlights – NPAT For personal use only NPAT $1,729m FX $16m NPAT $1,713m $1,337m @CC1 +28% @CC¹ FY17 FY18 1 Constant Currency (CC) removes the impact of exchange rate movements facilitating comparability of operational performance. See end note for further detail. 15 | Driven by Our Promi
Slide 16: Financial Highlights – Group
Financial Highlights – Group For personal use only Full year ended Jun FY17 FY18 FY18 Change US$ Millions Reported Reported at CC1 % Total Revenue 6,947 7,915 7,717 11%1 EBIT 1,779 2,380 2,358 33%1 EBIT margin 25.6% 30.1% 30.6% NPAT 1,337 1,729 1,713 28%1 Cashflow from Operations 1,247 1,902 - 53% R
Slide 17: Financial Highlights – Segments
Financial Highlights – Segments For personal use only CSL BEHRING SEQIRUS FY17 FY18 Change FY17 FY18 Change US$ Millions US$ Millions Reported Reported % at CC1 Reported Reported % at CC1 Sales 5,835 6,678 11% Sales 781 910 15% Other Other 188 149 (21%) 143 178 22% Revenue Revenue Total Total 6,023
Slide 18: Margin Growth
Margin Growth For personal use only TAILWINDS % EBITDA Margin 40 • rCOAGs sales growth • Helixate supply conclusion 35 Seqirus • Specialty products growth formation • IG mix shift 30 • Seqirus – transition to profitability HEADWINDS 25 • Increase in plasma CPL • US labour cost growth 18 | Driven by
Slide 19: Investing for Growth
Investing for Growth For personal use only $M Capital Expenditure DRIVERS 1,400 1,200 • New products 1,000 • Growth in existing products 800 • New facilities and modernization 600 • Expansion of FLUAD manufacturing 400 200 0 FY17 FY18 FY19 Est Maintenance Growth 19 | Driven by Our Promise™
Slide 20: Capital Allocation
Capital Allocation For personal use only FY18 • Dividends +26% • Residual share buyback R&D Dividends program • 2/3 capex growth related Share M&A buybacks Growth • R&D expensed not capitalised Capex Maint • >50% of R&D directed towards M&A Capex new product development 20 | Driven by Our Promise™
Slide 21: Delivering Shareholder Returns
Delivering Shareholder Returns For personal use only Net Profit After Tax / Total Dividends per Share $m Earnings per Share $ $ 2,000 4.00 1.80 1,800 3.80 1.70 1,600 3.60 1.60 1,400 3.40 1.50 1,200 3.20 1.40 1,000 3.00 1.30 800 2.80 1.20 600 2.60 1.10 400 2.40 1.00 200 2.20 0.90 0 2.00 0.80 2014 201
Slide 22: Outlook for FY19
Outlook for FY191 For personal use only • Continued strong demand for plasma and recombinant products • Margin growth from plasma product mix shift, specialty and NPAT ~$1,880m recombinant products growth & conclusion of HELIXATE® supply to $1,950m2 • CSL's collections growth expected to outpace the
Slide 23: Financial Appendix
For personal use only Financial Appendix 23 | Driven by Our Promise™
Slide 24: CSL Behring Revenue
CSL Behring Revenue For personal use only Year ended June Jun 2017 Jun 2018 Jun 2018 Change US$ Millions CC1 %1 Immunoglobulins 2,774 3,145 3,065 11% Albumin 840 921 896 7% Haemophilia - Recombinants 461 533 514 12% - Plasma 562 580 557 -1% Specialty 1,174 1,490 1,454 24% Other sales (mainly plasma)
Slide 25: Seqirus Revenue
Seqirus Revenue For personal use only Year ended June Jun 2017 Jun 2018 Jun 2018 Change US$ Millions CC1 %1 QIV 163 342 341 109% Influenza TIV 218 195 189 -13% vaccines +53%1 Adjuvanted 57 140 138 142% Other / In-licence 343 233 232 -32% Total Product Sales 781 910 900 15% Pandemic 94 118 114 21% Ro
Slide 26: Notes
Notes For personal use only (#) Constant currency removes the impact of exchange rate movements to facilitate comparability of operational performance for the Group. This is done in three parts: a) by converting the current year net profit of entities in the group that have reporting currencies othe
Slide 27: Contact
CSL Limited For personal use only Contact: Mark Dehring VP Investor Relations +61 3 9389 3407 mark.dehring@csl.com.au 27 | Driven by Our Promise™